Cargando…

Biology and Management of High-Grade Chondrosarcoma: An Update on Targets and Treatment Options

This review provides an overview of histopathology, clinical presentation, molecular pathways, and potential new systemic treatments of high-grade chondrosarcomas (CS), including grade 2–3 conventional, dedifferentiated, and mesenchymal CS. The diagnosis of CS combines radiological and histological...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tlemsani, Camille, Larousserie, Frédérique, De Percin, Sixtine, Audard, Virginie, Hadjadj, Djihad, Chen, Jeanne, Biau, David, Anract, Philippe, Terris, Benoit, Goldwasser, François, Pasmant, Eric, Boudou-Rouquette, Pascaline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862566/ https://www.ncbi.nlm.nih.gov/pubmed/36674874 http://dx.doi.org/10.3390/ijms24021361

Ejemplares similares

Relation between Plasma Trough Concentration of Pazopanib and Progression-Free Survival in Metastatic Soft Tissue Sarcoma Patients
por: Minot-This, Marie-Sophie, et al.
Publicado: (2022)

First referral to an integrated onco-palliative care program: a retrospective analysis of its timing
por: Barth, Claire, et al.
Publicado: (2020)

Pituitary Lesion of Unknown Origin: Think Epithelioid Angiosarcoma
por: Bricaire, Léopoldine, et al.
Publicado: (2017)

Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study
por: Boudou-Rouquette, Pascaline, et al.
Publicado: (2021)

Association of Energy Expenditure and Efficacy in Metastatic Renal Cell Carcinoma Patients Treated with Nivolumab
por: Noel, Johanna, et al.
Publicado: (2022)

Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients
por: Huillard, O, et al.
Publicado: (2013)

Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study
por: Tiako Meyo, Manuela, et al.
Publicado: (2020)

Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular Carcinoma
por: Mir, Olivier, et al.
Publicado: (2012)

Integrated molecular characterization of chondrosarcoma reveals critical determinants of disease progression
por: Nicolle, Rémy, et al.
Publicado: (2019)

Differential Kinase Activation in Peripheral Blood Mononuclear Cells from Non-Small-Cell Lung Cancer Patients Treated with Nivolumab
por: Noé, Gaëlle, et al.
Publicado: (2019)

Is there an Exposure–Response Relationship for Nivolumab in Real-World NSCLC Patients?
por: Bellesoeur, Audrey, et al.
Publicado: (2019)

Prognostic Factors and Treatment Options for Patients with High-Grade Chondrosarcoma
por: Gao, Zhongyang, et al.
Publicado: (2019)

Evidence for IL-35 Expression in Diffuse Large B-Cell Lymphoma and Impact on the Patient's Prognosis
por: Larousserie, Frédérique, et al.
Publicado: (2019)

The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort
por: Damotte, Diane, et al.
Publicado: (2019)

Early Sorafenib-Induced Toxicity Is Associated with Drug Exposure and UGTIA9 Genetic Polymorphism in Patients with Solid Tumors: A Preliminary Study
por: Boudou-Rouquette, Pascaline, et al.
Publicado: (2012)

Embryonic signature distinguishes pediatric and adult rhabdoid tumors from other SMARCB1-deficient cancers
por: Richer, Wilfrid, et al.
Publicado: (2017)

Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer
por: Mogenet, Alice, et al.
Publicado: (2023)

Total Scapular Prosthesis, an Option for the Treatment of Scapular Chondrosarcoma
por: Himer, Nabile, et al.
Publicado: (2023)

A colonic mass revealing a disseminated crystal storing histiocytosis secondary to indolent multiple myeloma: a case report with literature review
por: Contejean, Adrien, et al.
Publicado: (2020)

The appropriate and sequential value of standard radiograph, computed tomography and magnetic resonance imaging to characterize a bone tumor
por: Gaume, M., et al.
Publicado: (2022)

Performance of Sonoelastography for predicting malignancy in soft tissue
por: Bodard, Sylvain, et al.
Publicado: (2022)

Proximal femur versus acetabular extra-articular resection of the hip joint for primary malignant bone tumors: a retrospective comparative review of 33 cases
por: Housset, Victor, et al.
Publicado: (2022)

Time is Money! Influence on Operating Theater and Sterilization Times of Patient-specific Cutting Guides and Single-use Instrumentation for Total Knee Arthroplasty: A Full Factorial Design of 136 Patients
por: Teissier, Victoria, et al.
Publicado: (2022)

Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of bone
por: van Oosterwijk, Jolieke G, et al.
Publicado: (2012)

Is Endoscopic Submucosal Dissection the Option for Early Gastric Cancer Patients with Contraindication to Surgery?
por: Farhat, Said, et al.
Publicado: (2010)

Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter Study
por: Velev, Maud, et al.
Publicado: (2021)

Distraction osteogenesis and arthrodesis as a new surgical option for chondrosarcoma in the distal tibia
por: Ouyang, Zhengxiao, et al.
Publicado: (2015)

EUS-guided pancreatic radiofrequency ablation: preclinical comparison of two currently available devices in a pig model
por: Barret, Maximilien, et al.
Publicado: (2019)

Characterization of the replication timing program of 6 human model cell lines
por: Hadjadj, Djihad, et al.
Publicado: (2016)

Low-Grade Chondrosarcoma of the Posterior Cricoid Plate
por: Moen, Christy M, et al.
Publicado: (2021)

Using Bayesian statistics to estimate the likelihood a new trial will demonstrate the efficacy of a new treatment
por: Biau, David J., et al.
Publicado: (2017)

NF1 mutations identify molecular and clinical subtypes of lung adenocarcinomas
por: Tlemsani, Camille, et al.
Publicado: (2019)

Body Composition in Patients with Radioactive Iodine-Refractory, Advanced Differentiated Thyroid Cancer Treated with Sorafenib or Placebo: A Retrospective Analysis of the Phase III DECISION Trial
por: Huillard, Olivier, et al.
Publicado: (2019)

Seeing the forest or the tree depends on personality: Evidence from process communication model during global/local visual search task
por: Lefebvre, Sixtine, et al.
Publicado: (2023)

Low-grade chondrosarcoma of the larynx: A case report
por: Vučković, Ljiljana, et al.
Publicado: (2021)

Tumor necrosis is an underappreciated histopathologic factor in the grading of chondrosarcoma
por: Lazarides, Alexander L., et al.
Publicado: (2023)

Imaging of chondrosarcomas
por: Ollivier, L, et al.
Publicado: (2003)

Chondrosarcoma of the Thorax
por: Rascoe, Philip A., et al.
Publicado: (2011)

Chondrosarcoma of the Heart
por: Kim, Do Jung, et al.
Publicado: (2015)

Chondrosarcoma of maxilla
por: Gawande, Madhuri, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_acnuktflr4cmkhn3qfcbv2kjki